Table 3.
Results of comparison of MMT of patients who underwent one treatment of cell therapy with 6 months follow-up (group 1)
| Muscles | Pre-mean | Post-mean (at 6 months FU) | Significance value (P<0.05) | Improved ms strength | Decreased ms strength | Stable ms strength | Total improvement$ | Percentage of improvement |
|---|---|---|---|---|---|---|---|---|
| Hip extensors | 6.11 | 6.81 | 0.001# | 29 | 5 | 28 | 57/62 | 91.93 |
| Knee extensors | 8.61 | 9.06 | 0.022# | 22 | 7 | 33 | 55/62 | 88.7 |
| Peronei | 7.32 | 7.52 | 0.016# | 7 | 0 | 55 | 62/62 | 100 |
| Tibialis anterior | 7.68 | 7.94 | 0.030# | 11 | 1 | 50 | 61/62 | 98.38 |
| Upper abdominals | 6.65 | 7.48 | 0.013# | 13 | 4 | 14 | 27/31 | 87.09 |
| Lower abdominals | 6.16 | 6.68 | 0.123* | 11 | 5 | 15 | 26/31 | 83.87 |
| Back extensors | 5.87 | 6.13 | 0.280* | 8 | 3 | 20 | 28/31 | 90.32 |
| Deltoid | 9.32 | 9.69 | 0.005# | 17 | 3 | 42 | 59/62 | 95.16 |
| Biceps | 8.84 | 9.06 | 0.225* | 13 | 7 | 42 | 55/62 | 88.7 |
| Triceps | 10.18 | 10.03 | 0.303* | 6 | 7 | 49 | 55/62 | 88.7 |
Notes: 31 patients, 62 muscles. # Indicates statistically significant difference between the groups. The difference is observed as a result of positive ranks indicating a greater number of muscles that improved in strength post-CT. * Indicates statistically insignificant difference between the groups. The insignificance is observed as a result of a greater number of muscles maintaining the muscle strength. $ Muscles where the strength was maintained are also considered to have improved as LGMD is a progressive disease with reduction in muscle strength over time.
Abbreviations: CT, cell therapy; FU, follow-up; LGMD, limb girdle muscular dystrophy; MMT, manual muscle testing; ms, muscles.